Tuesday, April 15, 2014

Drosophila studies & cancer -- three new reports

Two reviews:

Markstein M. Modeling colorectal cancer as a 3-dimensional disease in a dish: the case for drug screening using organoids, zebrafish, and fruit flies. Drug Discov Today Technol. 2013  Spring;10(1):e73-81. PMID: 24050233.  
From the abstract: "This review discusses recent shifts in the understanding of colorectal cancer as a stem cell based disease ... recent advances in the culturing of colorectal stem cells using mammalian organoids, zebrafish, and Drosophila offer promising avenues for anti-CSC drug discovery."

Das TK, Cagan RL. A Drosophila approach to thyroid cancer therapeutics. Drug Discov Today Technol. 2013 Spring;10(1):e65-71. PMID: 24050232; PMCID: PMC3779345.  
From the abstract: "... In this review, we examine the contributions of work in the fruit fly Drosophila toward multiple endocrine neoplasia type 2 (MEN2), a Ret-based disease to which recent Drosophila models have proven useful both for understanding disease mechanism as well as helping identify new generation therapeutics."

And a research resport:

Lourenço FC, Munro J, Brown J, Cordero J, Stefanatos R, Strathdee K, Orange C, Feller SM, Sansom OJ, Vidal M, Murray GI, Olson MF. Reduced LIMK2 expression in colorectal cancer reflects its role in limiting stem cell proliferation. Gut.2014 Mar;63(3):480-93. PMID: 23585469; PMCID: PMC3932979.

From the abstract: "... Genetic analysis in Drosophila midgut and intestinal epithelial cells isolated from genetically modified mice revealed a conserved role for LIMK2 in constraining gastrointestinal stem cell proliferation. ..."

No comments:

Post a Comment